{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:16:03Z","timestamp":1762506963806,"version":"3.40.5"},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.bulcan.2016.11.007","type":"journal-article","created":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T09:35:09Z","timestamp":1481621709000},"page":"208-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Incidence et facteurs de risque de l\u2019enc\u00e9phalopathie \u00e0 l\u2019ifosfamide chez les patients suivis pour un sarcome"],"prefix":"10.1016","volume":"104","author":[{"given":"Natacha","family":"Stern","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilyes","family":"Sakji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Sophie","family":"Defachelles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5343-086X","authenticated-orcid":false,"given":"Cyril","family":"Lervat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Ryckewaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Marliot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Peugniez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Deplanque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Penel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2016.11.007_bib0085","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00776-009-1431-y","article-title":"Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity and risk factors","volume":"15","author":"Tajino","year":"2010","journal-title":"J Orthop Sci"},{"key":"10.1016\/j.bulcan.2016.11.007_bib0090","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4143\/crt.2011.43.4.260","article-title":"Fatal Ifosfamide-induced metabolic encephalopathy in patients with recurrent epithelial ovarian cancer: report of two cases","volume":"43","author":"Shin","year":"2011","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.bulcan.2016.11.007_bib0095","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/annonc\/mdm104","article-title":"Antiemetic neurokinin-1\u00a0antagonist aprepitant and ifosfamide-induced encephalopathy","volume":"18","author":"Durand","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2016.11.007_bib0100","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/15563658908994426","article-title":"Ifosfamide encephalopathy","volume":"27","author":"Danesh","year":"1989","journal-title":"J Toxicol Clin Toxicol"},{"key":"10.1016\/j.bulcan.2016.11.007_bib0105","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2165\/00002018-200831110-00003","article-title":"Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature","volume":"31","author":"Sweiss","year":"2008","journal-title":"Drug Saf"},{"key":"10.1016\/j.bulcan.2016.11.007_bib0110","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.coc.0000158439.02724.5a","article-title":"Evaluating risk factors for the development of ifosfamide encephalopathy","volume":"28","author":"David","year":"2005","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.11.007_bib0115","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/1078155214527143","article-title":"An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center","volume":"21","author":"Szabatura","year":"2015","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.bulcan.2016.11.007_bib0120","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1078155208093930","article-title":"Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant","volume":"14","author":"Howell","year":"2008","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.bulcan.2016.11.007_bib0125","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1177\/1078155210385159","article-title":"Evaluation of methylene blue, thiamine, and\/or albumin in the prevention of ifosfamide-related neurotoxicity","volume":"17","author":"Richards","year":"2011","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.bulcan.2016.11.007_bib0130","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1592\/phco.30.8.812","article-title":"Effectiveness of exogenous albumin administration for the prevention of ifosfamide-induced encephalopathy","volume":"30","author":"Kettle","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bulcan.2016.11.007_bib0135","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jfma.2015.07.016","article-title":"Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: a retrospective analysis","volume":"115","author":"Lo","year":"2016","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.bulcan.2016.11.007_bib0140","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/pbc.25724","article-title":"Ifosfamide-induced encephalopathy due to a novel formulation of ifosfamide","volume":"63","author":"Filhon","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bulcan.2016.11.007_bib0145","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/0277-5379(86)90368-8","article-title":"Prediction of ifosfamide\/mesna associated encephalopathy","volume":"22","author":"Meanwell","year":"1986","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2016.11.007_bib0150","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0090-8258(91)90344-5","article-title":"Ifosfamide-induced neurotoxicity","volume":"42","author":"Curtin","year":"1991","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2016.11.007_bib0155","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00001813-200404000-00006","article-title":"Incidence and severity of ifosfamide-induced encephalopathy","volume":"15","author":"Rieger","year":"2004","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.bulcan.2016.11.007_bib0080","doi-asserted-by":"crossref","first-page":"868973","DOI":"10.1155\/2013\/868973","article-title":"Clinical activity and tolerability of a 14-day infusional ifosfamide schedule in soft-tissue sarcoma","volume":"2013","author":"Martin-Liberal","year":"2013","journal-title":"Sarcoma"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455116303186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455116303186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T21:54:31Z","timestamp":1536184471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455116303186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0007455116303186"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2016.11.007","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence et facteurs de risque de l\u2019enc\u00e9phalopathie \u00e0 l\u2019ifosfamide chez les patients suivis pour un sarcome","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2016.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}